Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab +/- Re-Irradiation for Recurrent Glioblastoma
NCT01730950Phase 2Completed
- Sponsor
- NRG Oncology
- Start
- Dec 2012
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in glioblastoma (GBM), sponsored by NRG Oncology. Started Dec 2012; status: completed.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01730950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01730950.